Skip to content
Menu
Network
Sub-Menu
Browse by Subject
Browse by Publisher
Join the Network
Get Started
Subscribe
Support
Contact Us
Search
Close
Enter Search Terms
Search
Harrison Gunn
ID:
1b83cf65-2619-30fb-68c4
/
Unclaimed
/
Organization:
Goodwin Procter
Published Works
32 articles
Mylan Voluntarily Recalls Additional Batch of Biosimilar Insulin Glargine Pens Due to Potential Missing Labels
Big Molecule Watch ·
July 8, 2022
cite
Outlook Therapeutics to Revise Ophthalmic Bevacizumab BLA in Light of FDA Request
Big Molecule Watch ·
May 31, 2022
cite
Celltrion to Enter U.S. Humira Biosimilar Market Following Patent Agreement with AbbVie
Big Molecule Watch ·
April 28, 2022
cite
FDA to Hold Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act
Big Molecule Watch ·
March 21, 2022
cite
Biogen and Xbrane Enter into Worldwide Commercialization and License Agreement for Certolizumab Pegol Biosimilar
Big Molecule Watch ·
February 15, 2022
cite
Previous
1
2
3
4
5
6
7
Next
